1,5,6,7-tetrahydro-indol-4-one oxime | 27866-27-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1,5,6,7-tetrahydro-indol-4-one oxime
• 英文别名: N-(1,5,6,7-tetrahydroindol-4-ylidene)hydroxylamine
• CAS: 27866-27-9
• 化学式: C₈H₁₀N₂O
• 分子量: 150.18
• InChiKey: NGYHNWRKMRIRFH-UHFFFAOYSA-N

物化性质

• 沸点：
  381.9±21.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  48.4
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1,5,6,7-tetrahydro-indol-4-one oxime 在 sodium hydride 、 二异丁基氢化铝 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 (1-Methyl-5,6,7,8-tetrahydropyrrolo[3,2-b]azepin-4-yl)-(4-nitrophenyl)methanone
  参考文献：
  名称：

  Regioselective Synthesis of Several Heterocyclic Fused Azepines Using Diisobutylaluminum Hydride

  摘要：

  5,6,7,8-Tetrahydrothieno[3,2-b]azepine,5,6,7,8-tetrahydro-1H-furo[3,- 2b]azepine, and 1,4,5,6,7,8-hexahydropyrrolo [3,2-b]azepine were synthesized by the ring expansion reaction of heterocyclic fused cyclohexanone oximes with diisobutylaluminum hydride (DIBAH). The mechanism of the reaction was different from that of Beckmann rearrangement.

  DOI：

  10.3987/com-98-8104
• 作为产物：
  描述：

  1,5,6,7-四氢-4H-吲哚-4-酮 在 吡啶 、 盐酸羟胺 作用下， 反应 2.0h， 生成 1,5,6,7-tetrahydro-indol-4-one oxime
  参考文献：
  名称：

  Regioselective Synthesis of Several Heterocyclic Fused Azepines Using Diisobutylaluminum Hydride

  摘要：

  5,6,7,8-Tetrahydrothieno[3,2-b]azepine,5,6,7,8-tetrahydro-1H-furo[3,- 2b]azepine, and 1,4,5,6,7,8-hexahydropyrrolo [3,2-b]azepine were synthesized by the ring expansion reaction of heterocyclic fused cyclohexanone oximes with diisobutylaluminum hydride (DIBAH). The mechanism of the reaction was different from that of Beckmann rearrangement.

  DOI：

  10.3987/com-98-8104

文献信息

• Heterocyclic-fused lactams promote release of growth hormone
  申请人：Merck & Co., Inc.

  公开号：US05606054A1

  公开（公告）日：1997-02-25

  There are disclosed certain novel compounds identified as heterocyclic-fused lactams which promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to increase the stature of those afflicted with a lack of a normal secretion of natural growth hormone. Growth promoting compositions containing such heterocyclic-fused lactams as the active ingredient thereof are also disclosed.

  本发明公开了一些新型化合物，其被识别为杂环融合内酰胺，可促进人类和动物的生长激素释放。这种特性可用于促进食用动物的生长，使可食用肉制品的生产更加高效，而在人类中，可增加那些患有正常生长激素分泌缺乏的人的身高。本发明还公开了含有这种杂环融合内酰胺作为活性成分的促生长组合物。
• 4-aryl substituted indolinones
  申请人：Sugen, Inc.

  公开号：US20030069297A1

  公开（公告）日：2003-04-10

  The present invention relates to 4-arylindolinones, as well as pharmaceutical compositions thereof, capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. The present invention also relates to methods for treating protein kinase related disorders.

  本发明涉及4-芳基吲哚酮及其药物组成物，能够调节蛋白激酶信号转导，以调节、调控和/或抑制异常细胞增殖。本发明还涉及治疗蛋白激酶相关疾病的方法。
• 4-Aryl substituted indolinones
  申请人：Sugen, Inc.

  公开号：US20040157909A1

  公开（公告）日：2004-08-12

  The present invention relates to 4-arylindolinones, as well as pharmaceutical compositions thereof, capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. The present invention also relates to methods for treating protein kinase related disorders.

  本发明涉及4-芳基吲哚酮，以及其制药组合物，能够调节蛋白激酶信号传导，以调节、调节和/或抑制异常细胞增殖。本发明还涉及用于治疗蛋白激酶相关疾病的方法。
• Synthesis and Structure−Activity Relationships of 5,6,7,8-Tetrahydro-4<i>H</i>-thieno[3,2-<i>b</i>]azepine Derivatives:  Novel Arginine Vasopressin Antagonists
  作者：Hidetsura Cho、Kengo Murakami、Hiroyuki Nakanishi、Akitaka Fujisawa、Hirotaka Isoshima、Misako Niwa、Kazuhide Hayakawa、Yasunori Hase、Itsuo Uchida、Hidenori Watanabe、Korekiyo Wakitani、Kazuo Aisaka

  DOI：10.1021/jm030287l

  日期：2004.1.1

  A variety of novel heterocyclic compounds having thienoazepine, pyrroloazepine, furoazepine, and thienodiazepine skeletons were synthesized, most of which exhibited potent antagonism of [H-3]-AVP specific binding in assays using rat liver (V1), rat kidney (V2), human platelet plasma membranes, and recombinant human CHO cells (V2), as well as antagonizing AVP-induced hypertension in rats (V1, intravenous) and showing a diuretic effect in rats (V2, oral). By detailed studies of the structure-activity relationships of these compounds, the thienoazepine derivative 1 was found to be a very potent combined V1 and V2 antagonist. After further pharmacological and toxicological evaluation as well as physical properties, the hydrochloride 2 (JTV-605) of compound 1 was selected for clinical studies as a potent AVP antagonist with a long duration of action.
• Regioselective Synthesis of Several Heterocyclic Fused Azepines Using Diisobutylaluminum Hydride
  作者：Hidetsura Cho、Kengo Murakami、Hiroyuki Nakanishi、Hirotaka Isoshima、Kazuhide Hayakawa、Itsuo Uchida

  DOI：10.3987/com-98-8104

  日期：——

  5,6,7,8-Tetrahydrothieno[3,2-b]azepine,5,6,7,8-tetrahydro-1H-furo[3,- 2b]azepine, and 1,4,5,6,7,8-hexahydropyrrolo [3,2-b]azepine were synthesized by the ring expansion reaction of heterocyclic fused cyclohexanone oximes with diisobutylaluminum hydride (DIBAH). The mechanism of the reaction was different from that of Beckmann rearrangement.